#1 Clinical Trials Search in Europe

Ecoo6A

Recent clinical trials have been exploring the potential of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. This vaccine, which contains the active substance ECOO6A among others, is being tested in adults aged 60 and older with a history of urinary tract infections. The trials aim to evaluate the vaccine’s efficacy, safety, and ability to stimulate an immune response against various strains of E. coli that can cause serious infections outside the intestinal tract.

Table of Contents

What is ExPEC9V?

ExPEC9V, also known as ECOO6A, is an investigational vaccine being developed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults[1]. This vaccine is designed to protect against specific strains of E. coli bacteria that can cause serious infections outside the intestinal tract.

Target Population

The ExPEC9V vaccine is primarily being studied in adults aged 60 years and older who have a history of urinary tract infections (UTIs) in the past two years[2]. This group is particularly vulnerable to invasive E. coli infections due to factors such as:

  • Weakened immune systems
  • Previous history of UTIs
  • Recent hospitalizations
  • Other underlying health conditions

How ExPEC9V Works

ExPEC9V is a multivalent vaccine, meaning it targets multiple strains of E. coli bacteria. Specifically, it aims to protect against nine E. coli serotypes: O1, O2, O4, O6, O15, O16, O18, O25, and O75[2]. These serotypes are commonly associated with invasive E. coli infections.

The vaccine works by stimulating the immune system to produce antibodies against these specific E. coli strains. When vaccinated individuals encounter these bacteria in the future, their immune system is better prepared to fight off the infection before it becomes severe.

Clinical Trials

ExPEC9V is currently being evaluated in Phase 3 clinical trials. These large-scale studies are designed to assess the vaccine’s effectiveness, safety, and immune response in the target population. Two notable trials include:

  1. A study comparing ExPEC9V with a high-dose quadrivalent influenza vaccine in adults aged 65 years or older[1].
  2. A trial specifically focused on adults aged 60 years and older with a history of UTIs, evaluating the vaccine’s ability to prevent invasive E. coli disease[2].

These trials aim to determine how well ExPEC9V can prevent various types of E. coli infections, including:

  • Invasive ExPEC disease (IED): Serious infections where E. coli enters the bloodstream or other normally sterile sites in the body
  • Urinary tract infections (UTIs): Including both simple and complicated UTIs
  • Pyelonephritis: A severe kidney infection
  • Bacteremia: The presence of bacteria in the blood
  • Sepsis: A life-threatening condition caused by the body’s response to infection

Potential Benefits

If proven effective, ExPEC9V could offer several benefits to older adults:

  • Reduced risk of severe E. coli infections
  • Fewer hospitalizations due to IED
  • Decreased incidence of UTIs and kidney infections
  • Improved quality of life for those prone to recurrent UTIs
  • Potential reduction in antibiotic use, helping combat antibiotic resistance

Safety and Side Effects

As with any vaccine, safety is a top priority in the development of ExPEC9V. The clinical trials are carefully monitoring for any adverse effects. Common side effects of vaccines may include:

  • Pain, redness, or swelling at the injection site
  • Mild fever
  • Fatigue
  • Headache
  • Muscle aches

The trials are specifically looking at both solicited (expected) and unsolicited (unexpected) adverse events in the short term, as well as any serious adverse events over a longer period[2].

Conclusion

ExPEC9V (ECOO6A) represents a promising advancement in the prevention of invasive E. coli infections in older adults. As the clinical trials progress, more information will become available about its effectiveness and safety profile. If successful, this vaccine could significantly reduce the burden of E. coli-related illnesses in vulnerable populations.

Aspect Details
Vaccine Name ExPEC9V (JNJ-78901563)
Target Population Adults aged 60+ with history of UTIs
Main Objectives Prevent invasive E. coli disease, assess safety and immune response
Administration Intramuscular injection
Key Components ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, ECOO75
Study Design Randomized, double-blind, placebo-controlled
Primary Endpoints Prevention of first IED event caused by specific E. coli serotypes
Secondary Endpoints Prevention of UTIs, pyelonephritis, hospitalization; immune response measurement

FAQ

  • What is ExPEC9V? ExPEC9V is a vaccine being developed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. It contains multiple components targeting different strains of E. coli, including ECOO6A.
  • Who is being studied in these clinical trials? The trials are focusing on adults aged 60 years and older with a history of urinary tract infections in the past two years. Some trials also include adults aged 65 years or older.
  • What are the main goals of these clinical trials? The main objectives are to assess the efficacy of ExPEC9V in preventing invasive E. coli disease, evaluate its safety and reactogenicity, and measure the immune response it generates in participants.
  • How is the vaccine administered? ExPEC9V is administered as an intramuscular injection. In some trials, it is being tested alongside other vaccines, such as the high-dose quadrivalent influenza vaccine.
  • What are the potential benefits of this vaccine? If successful, ExPEC9V could help prevent serious E. coli infections, including those in the blood and urinary tract, potentially reducing hospitalizations and improving quality of life for older adults at risk of these infections.

Ongoing Clinical Trials on Ecoo6A

  • Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • Study of ExPEC9V vaccine for preventing invasive E.

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany The Netherlands Spain +1

Glossary

  • ExPEC: Extraintestinal Pathogenic Escherichia coli, strains of E. coli that can cause infections outside the intestinal tract, such as urinary tract infections and bloodstream infections.
  • Invasive E. coli Disease (IED): A serious infection caused by E. coli bacteria that spreads beyond the initial site of infection, such as into the bloodstream or other normally sterile sites in the body.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Reactogenicity: The capacity of a vaccine to produce common, expected adverse reactions, usually at the injection site or as general symptoms like fever.
  • Urinary Tract Infection (UTI): An infection in any part of the urinary system, including kidneys, bladder, ureters, and urethra, often caused by bacteria such as E. coli.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ failure.

References

  1. http://clinicaltrials.eu/trial-id/2023-504168-40-00
  2. http://clinicaltrials.eu/trial/study-on-jnj-78901563-vaccine-for-preventing-invasive-e-coli-disease-in-adults-60-with-recent-urinary-tract-infections/